Imagine a disease that has claimed more lives throughout history than any other—a silent killer that still takes over a million lives each year. Tuberculosis (TB) is that relentless foe, and Bryan Bryson, an associate professor at MIT, is on a mission to outsmart it. But here’s where it gets controversial: while many researchers focus on new antibiotics, Bryson believes the real game-changer lies in understanding how our immune cells actually fight TB. Could this shift in focus be the key to a vaccine that works for everyone? Let’s dive in.
Bryson’s journey began at MIT, where he initially grappled with choosing a major. With a family legacy in engineering—his great-grandfather worked on the Panama Canal, and his grandmother was a natural builder—he was drawn to the field. Yet, it was a summer internship that steered him toward a broader path. His mentor’s advice? ‘Study something that gives you options, because the world will change.’ This wisdom led him to mechanical engineering with a bioengineering focus, a decision that would shape his future.
Working in Linda Griffith’s lab, Bryson built microfluidic devices to grow liver tissue, but he soon realized he wanted to dig deeper into why cells behave the way they do. This curiosity propelled him to earn a PhD in biological engineering, where he studied cell signaling in diseases like cancer and diabetes. It was during his postdoctoral work with immunologist Sarah Fortune that TB became his obsession. Fortune challenged him to think boldly: not just finding new treatments, but transformative solutions that could drastically reduce TB’s global impact.
And this is the part most people miss: Bryson’s approach isn’t just about studying TB—it’s about measuring it. ‘Making a better TB vaccine is a question of measurement,’ he says. His lab at MIT has developed groundbreaking methods to identify which bacterial proteins are displayed by infected cells, a critical step in designing an effective vaccine. Out of the 4,000 proteins produced by Mycobacterium tuberculosis, only a handful are presented to the immune system, and these vary depending on a person’s genetic background. By analyzing blood samples from diverse populations, Bryson’s team has already pinpointed the proteins displayed in about 50% of people. Once they crack the remaining 50%, they’ll have a blueprint for a vaccine that could work for nearly everyone.
But here’s the bold question: What if the key to ending TB isn’t just in the lab, but in how we think about the problem? Bryson credits his mother’s unwavering optimism for his resilience. Raised by a single mother who made it all look effortless, he learned that challenges aren’t roadblocks—they’re opportunities. This mindset fuels his work at MIT, where the ‘can-do’ engineer ethos aligns perfectly with his mission. When he’s not in the lab, Bryson brings this optimism to Simmons Hall, where he’s known for whipping up gallons of ice cream—think passion fruit or jalapeño strawberry—for dorm residents. ‘Toasted marshmallow was a huge hit, but it destroyed my kitchen,’ he laughs.
As Bryson and his team work toward clinical trials in the next six years, the question remains: Can engineering truly outsmart one of history’s deadliest diseases? And if so, what other global health challenges could this approach tackle? What do you think—is Bryson’s focus on immune cell behavior the right path, or should we double down on antibiotics instead? Let’s spark the debate in the comments!
